BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

BioNTech SENASDAQ: BNTX

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation outflow grows to €0

Q2 FY2026 stock-based compensation was €0, compared with €0 a year earlier. Trailing-twelve-month stock-based compensation was €0.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 3.7 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near €0 or moves back toward the trailing-twelve-month quarterly average of €0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
€0— QoQ
Last fiscal yearDec 2025
€0-100.0% YoY
LTMJun 2026
€0— YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

EUR · from the cash flow

Latest · FY2025
0 EUR
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Stock-based compensation amounts to 0.0% of revenue for BNTX, versus a peer median of 8.9%.
BNTX Competitors
Stock-Based Compensation for BNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$187.88M USD-31.7%+9.8%3.2%
TGTXTG Therapeutics, Inc.LTM Sep 2026$88.18M USD+44.6%+49.9%9.8%
GMABGenmab A/SLTM Jun 2026$71M USD——1.7%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$46.65M USD-42.2%-9.8%12.3%
XNCRXencor, Inc.LTM Jun 2026$39.03M USD+10.2%-4.0%37.2%
IBRXImmunityBio, Inc.LTM Sep 2026$34.15M USD-8.0%-2.9%18.7%
IMCRImmunocore Holdings plcLTM Mar 2026$28.21M USD+14.1%—7.3%
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
IMTXImmatics N.V.LTM Mar 2026€7.38M EUR-44.8%—19.8%
BNTXBioNTech SELTM Jun 2026€0 EUR——0.0%
CGENCompugen Ltd.LTM Dec 2025$0 USD——0.0%
Peer median (excluding BNTX) —-19.8%-3.5%8.9%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.05B12.95B1.19B(677.7M)(1.09B)
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
Deferred Income Tax000070.98M
Stock-Based Compensation93.9M108.6M51.4M100.9M0
Change in Working Capital(10.73B)4.52B5.57B1.22B516.57M
Accounts Receivables(11.81B)4.37B5.37B387.7M1.04B
Inventory(438.4M)62.9M81.9M74.5M170.88M
Accounts Payables1.52B85.7M118.9M758.4M(695.23M)
Other Working Capital00000
Other Non-Cash Items(3.6B)(4.13B)(1.62B)(734.1M)574.01M
Operating Cash Flow889.7M13.58B5.37B207.7M438M
Capital Expenditures(154M)(363.3M)(705.5M)(452.3M)(168.19M)
Acquisitions (Net)(20.8M)0(336.9M)0183.27M
Purchases of Investments(394.7M)(47.8M)(6.98B)(12.37B)(10.97B)
Sales of Investments0375.2M1.19B10.74B9.14B
Other Investing Activities(23.1M)(33.5M)(576.59M)(164.6M)0
Investing Cash Flow(566.1M)(35.3M)(6.95B)(2.08B)(2.37B)
Debt Repayment(66.7M)(59.1M)(40.1M)(45.9M)(10.85M)
Common Stock Issued160.9M110.5M000
Common Stock Repurchased0(986.4M)(738.5M)00
Dividends Paid0(484.3M)000
Other Financing Activities0000(39.96M)
Financing Cash Flow94.2M(1.42B)(778.6M)(45.9M)(50.81M)
Effect of Forex Changes64.7M60.1M150.3M14.8M1.05B
Net Change in Cash482.5M12.18B(2.21B)(1.9B)(931.17M)
Free Cash Flow735.7M13.21B4.67B(244.6M)269.81M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.